Table 9.
Pediatric leukemia trials with autologous T-cells against CD-19 in http://www.clinicaltrials.gov
| Number | Abbreviated title | NCT number | Age | Sponsor |
|---|---|---|---|---|
| 1 | A pediatric trial of genetically modified autologous T-cells directed against CD19 for R/CD19+ ALL | 01683279 | 1–26 years | Seattle Children’s Hospital |
| 2 | Redirected autologous T-cells engineered to contain humanized anti-CD19 in R/R CD19+ leukemia and lymphoma previously treated with cell therapy | 02374333 | 1–24 years | University of Pennsylvania |
| 3 | CART19 cells for patients with chemotherapy-resistant or chemotherapy-refractory CD19+ leukemia and lymphoma | 01626495 | 1–24 years | Children’s Hospital of Philadelphia |
| 4 | Immunotherapy with CD19 CAR T-cells for CD19+ hematological malignancies | 02443831 | ≤24 years | University College London |
| 5 | Autologous T-lymphocytes genetically targeted to the B-cell specific antigen CD19 in pediatric and young adult patients with relapsed B-cell ALL | 01860937 | ≤26 years | Memorial Sloan Kettering Cancer Center |
| 6 | Anti-CD19 CAR-transduced T-cell therapy for patients with B-cell malignancies | 02456350 | 1–85 years | Shenzhen Second People’s Hospital, People’s Republic of China |
| 7 | T-cells or EBV-specific CTLs, advanced B-cell NHL and CLL | 00709033 | ? | Baylor College of Medicine |
| 8 | Treatment of relapsed and/or chemotherapy-refractory B-cell malignancy by CART19 | 01864889 | 5–90 years | Chinese PLA General Hospital |
Abbreviations: NCT, National Clinical Trial; ALL, acute lymphoblastic leukemia; CAR, chimeric antigen receptor; NHL, non-Hodgkin lymphoma; PLA, People’s Liberation Army; R/R, relapsed or refractory; EBV, epstein barr virus; CTL, cytotoxic T-Lymphocyte; CLL, chronic lymphocytic leukemia.